Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
Acambis, in collaboration with Aventis Pasteur, is developing a chimeric vaccine based on a recombinant yellow fever vaccine for the potential prevention of dengue virus infection. The vaccine is undergoing phase I clinical trials.
ID Biomedical Corp, 7150 Frederick Banting, Montreal, H4S 2A1, Quebec, Canada. tjones@idbiomedical.com
Taff
T
Jones
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D003715:Dengue / Q000517:prevention & control*; D003716:Dengue Virus / Q000235:genetics* / Q000276:immunology* / Q000472:pathogenicity; D004353:Drug Evaluation, Preclinical; D006801:Humans; D019595:Severe Dengue / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology / Q000633:toxicity; D014765:Viral Vaccines / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D053060:West Nile Virus Vaccines
D000914:Antibodies, Viral; C445780:ChimeriVax; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D053060:West Nile Virus Vaccines